Repligen (NASDAQ:RGEN - Get Free Report) posted its quarterly earnings results on Thursday. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03, Zacks reports. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. Repligen updated its FY 2025 guidance to 1.670-1.760 EPS.
Repligen stock traded up $12.46 during mid-day trading on Thursday, reaching $163.19. 425,022 shares of the stock traded hands, compared to its average volume of 560,983. The stock has a market capitalization of $9.14 billion, a PE ratio of -441.03, a price-to-earnings-growth ratio of 4.08 and a beta of 0.99. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. Repligen has a 12-month low of $113.50 and a 12-month high of $203.13. The business's 50-day moving average is $155.04 and its 200-day moving average is $148.71.
RGEN has been the subject of several analyst reports. StockNews.com upgraded Repligen from a "sell" rating to a "hold" rating in a research note on Friday, January 3rd. TD Cowen started coverage on Repligen in a research report on Monday, February 10th. They set a "buy" rating and a $200.00 price target for the company. HC Wainwright dropped their price target on Repligen from $240.00 to $180.00 and set a "buy" rating for the company in a research report on Thursday, January 23rd. Canaccord Genuity Group initiated coverage on Repligen in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 price target for the company. Finally, Canaccord Genuity Group initiated coverage on Repligen in a report on Tuesday, December 17th. They set a "hold" rating and a $165.00 price objective on the stock. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $182.91.
Get Our Latest Stock Analysis on RGEN
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.